14.72 -0.24 (-1.6%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 22.07 | 1-year : | 25.55 |
Resists | First : | 18.9 | Second : | 21.87 |
Pivot price | 15.68 | |||
Supports | First : | 14.07 | Second : | 11.71 |
MAs | MA(5) : | 14.55 | MA(20) : | 16.88 |
MA(100) : | 12.38 | MA(250) : | 8.24 | |
MACD | MACD : | -0.7 | Signal : | -0.3 |
%K %D | K(14,3) : | 7.2 | D(3) : | 5 |
RSI | RSI(14): 40.2 | |||
52-week | High : | 21.87 | Low : | 4.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MGNX ] has closed above bottom band by 26.7%. Bollinger Bands are 8.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 15.3 - 15.38 | 15.38 - 15.45 |
Low: | 14.03 - 14.15 | 14.15 - 14.24 |
Close: | 14.55 - 14.72 | 14.72 - 14.86 |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Thu, 28 Mar 2024
MacroGenics (NASDAQ:MGNX) Stock Price Down 3.6% - MarketBeat
Fri, 22 Mar 2024
Exchange Traded Concepts LLC Boosts Holdings in MacroGenics, Inc. (NASDAQ:MGNX) - Defense World
Thu, 14 Mar 2024
MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 07 Mar 2024
MacroGenics Provides Update on Corporate Progress and 2023 Financial Results - Yahoo Finance
Thu, 07 Mar 2024
MacroGenics, Inc. (MGNX) Q4 2023 Earnings Call Transcript - Seeking Alpha
Thu, 07 Mar 2024
Macrogenics Inc (MGNX) Reports Strong Financial Position and Advancements in Cancer Treatment ... - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 62 (M) |
Shares Float | 52 (M) |
Held by Insiders | 2.6 (%) |
Held by Institutions | 100 (%) |
Shares Short | 5,020 (K) |
Shares Short P.Month | 8,340 (K) |
EPS | -0.16 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 2.46 |
Profit Margin | -15.5 % |
Operating Margin | -460.4 % |
Return on Assets (ttm) | -36.4 % |
Return on Equity (ttm) | -6.2 % |
Qtrly Rev. Growth | -85.4 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0.94 |
EBITDA (p.s.) | -2.55 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -78 (M) |
Levered Free Cash Flow | -25 (M) |
PE Ratio | -98.14 |
PEG Ratio | 0 |
Price to Book value | 5.98 |
Price to Sales | 15.64 |
Price to Cash Flow | -11.76 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |